Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma

Leukemia

Volumn 25, Issue 6, 2011, Pages 1026-1035

  Chng, W J ^a,b,c,g   Huang, G F ^b   Chung, T H ^c   Ng, S B ^d   Gonzalez Paz, N ^e   Troska Price, T ^e   Mulligan, G ^f   Chesi, M ^a   Bergsagel, P L ^a   Fonseca, R ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e MAYO CLINIC   (United States)

^f MILLENNIUM PHARMACEUTICALS INC   (United States)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

bortezomib; hyperdiploid; MGUS; MYC; myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MYC PROTEIN; RAS PROTEIN; SYNDECAN 1;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 79958095463     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.53     Document Type: Article

References (51)

1. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
2. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
3. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571-596. (Pubitemid 350215376)
4. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156-2161. (Pubitemid 41291733)
5. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424. (Pubitemid 34864300)
6. Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879-1882. (Pubitemid 39530019)
7. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569. (Pubitemid 34438817)
8. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008; 22: 2280-2284.
9. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317-323. (Pubitemid 40053099)
10. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757. (Pubitemid 34533050)
11. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700. (Pubitemid 46239604)
12. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982-2989. (Pubitemid 46724834)
13. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
14. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.
15. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-180. (Pubitemid 351163163)
16. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 2003; 34: 226-230. (Pubitemid 36666937)
17. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357. (Pubitemid 43128862)
18. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108: 2755-2763.
19. Yustein JT, Liu YC, Gao P, Jie C, Le A, Vuica-Ross M et al. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci USA 2010; 107: 3534-3539.
20. Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS et al. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer 2000; 87: 787-793. (Pubitemid 30660555)
21. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW et al. Control of cell growth by c-Myc in the absence of cell division. Curr Biol 1999; 9: 1255-1258. (Pubitemid 29527152)
22. Schlee M, Krug T, Gires O, Zeidler R, Hammerschmidt W, Mailhammer R et al. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV. J Virol 2004; 78: 3941-3952. (Pubitemid 38437200)
23. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231. (Pubitemid 351969894)
24. Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. Blood 2009; 114: 2448-2458.
25. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 2005; 24: 6231-6240.
26. Schlee M, Holzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007; 120: 1387-1395. (Pubitemid 46355371)
27. You Z, Madrid LV, Saims D, Sedivy J, Wang CY. c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kappa B transactivation. J Biol Chem 2002; 277: 36671-36677.
28. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 2007; 104: 19488-19493.
29. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144. (Pubitemid 47208626)
30. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187. (Pubitemid 37328787)
31. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008; 2008: 25-31.
32. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495. (Pubitemid 46572539)
33. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-2514.
34. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999; 3: 169-179. (Pubitemid 29292618)
35. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24: 627-637.
36. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114: e20-e26.
37. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885-12890.
38. Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF et al. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res 2008; 68: 10215-10222.
39. Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A. IL-6- induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem 2011; 286: 67-78.
40. Chiecchio L, Dagrada GP, Protheroe RK, Stockley DM, Smith AG, Orchard KH et al. Loss of 1p and rearrangement ofMYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009; 94: 1024-1028.
41. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr. J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303. (Pubitemid 40967205)
42. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007; 448: 445-451. (Pubitemid 47123512)
43. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1-11. (Pubitemid 29018404)
44. Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004; 23: 3217-3221. (Pubitemid 38638833)
45. Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 1999; 96: 13180-13185.
46. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442. (Pubitemid 43855046)
47. Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14: 492-496. (Pubitemid 23191958)
48. Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 2008; 111: 3867-3871.
49. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
50. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007; 13: 820-827. (Pubitemid 47038193)
51. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.